Day: November 12, 2024

NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc.  (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. “Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “We believe that CARDAMYST has the potential to improve how PSVT is managed and positions Milestone to deliver meaningful value to patients, providers, and payors. Complementing our efforts in PSVT, we are very encouraged by clinician interest in the etripamil Phase 3 study in AFib-RVR which we are working toward...

ASHBURN, Va., Nov. 12, 2024 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, has posted its 2024 third quarter financial results on its investor relations website at https://investors.telos.com. Telos will host a live webcast to discuss its third quarter 2024 financial results today, November 12, 2024, at 10:30 a.m. EST. To access the webcast, visit https://register.vevent.com/register/BIdfd71e0c66a04ad886e4545430153f2b. Related presentation materials will be made available on the Investors section of the Company’s website at https://investors.telos.com. In addition, an archived webcast will be available approximately two hours after the conclusion of the live event on the Investors section of the Company’s...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1 dose-escalation studies of small molecule drug-conjugate (SMDC), VIP236, and CDK9 inhibitor, enitociclib, and identified the maximum tolerated dose Expected cash runway into early 2025 PALO ALTO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter of 2024 and provided an overview of its clinical programs and anticipated milestones. “As we direct our efforts and resources toward our ADC technologies and programs, we are committed...

LOS ALAMITOS, Calif. and LAS VEGAS, Nov. 12, 2024 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), the company behind MARKET.live, a leading livestream social shopping platform, and GO FUND YOURSELF!, a TV show and innovative new platform disrupting the crowd funding industry, today announced that on November 5, 2024, the Company filed its Form 10-Q report for the quarter ending September 30, 2024 demonstrating substantial and continuing financial improvements. In addition to the financial improvements, the report also highlights significant strategic initiatives and operational achievements. Financial HighlightsThe Company reported notable financial performance metrics for the quarter:Balance Sheet: $15.8 million in cash, short-term investments, and pre-paid expensesStockholders’...

LIMASSOL, Cyprus, Nov. 12, 2024 (GLOBE NEWSWIRE) — Toro Corp. (NASDAQ: TORO), (“Toro”, or the “Company”), an international energy transportation services company, today announced its results for the three months and the nine months ended September 30, 2024. Highlights of the Third Quarter Ended September 30, 2024:Total vessel revenues from continuing operations: $5.3 million, as compared to $6.5 million for the three months ended September 30, 2023, or a 18.5% decrease; Net income from continuing operations: $1.0 million, as compared to $0.2 million for the three months ended September 30, 2023, or a 400.0% increase; Net income: $1.0 million, as compared to $35.1 million for the three months ended September 30, 2023, or a 97.2% decrease; Loss per common share, basic from continuing operations: $(0.01) per share, as compared to...

OLD GREENWICH, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) — Hudson Global, Inc. (Nasdaq: HSON) (“Hudson Global” or “the Company”), a leading global total talent solutions company, announced today financial results for the third quarter ended September 30, 2024. 2024 Third Quarter SummaryRevenue of $36.9 million decreased 6.5% from the third quarter of 2023 and 8.1% in constant currency. Adjusted net revenue of $18.6 million decreased 4.0% from the third quarter of 2023 and 5.2% in constant currency. Net loss was $0.8 million, or $0.28 per diluted share, compared to net income of $0.5 million, or $0.17 per diluted share, for the third quarter of 2023. Adjusted net loss per diluted share (non-GAAP measure)* was $0.13 compared to adjusted net income per diluted share of $0.24 in the third quarter of 2023. Adjusted...

Tuesday, Schouw & Co. released its interim report for the third quarter of 2024; As expected, consolidated revenue for Q3 2024 was down on the year before, driven by a drop in volume sales combined with lower prices. EBITDA was also down compared to the very strong Q3 2023. Cash flows from operations remained at a high level. HighlightsDKK 9.5bn revenue – a reduction of 9% DKK 834m EBITDA – a decrease of 8% DKK 1.2bn cash flows from operations – a reduction of DKK 0.3bn DKK 14.6 earnings per share – a decrease of 14% 13.3% ROIC excluding goodwill – an increase of 0.9 ppStatement by Jens Bjerg Sørensen, President of Schouw & Co. – Overall, Q3 2024 was a good quarter for Schouw & Co. with solid profitability and continued strong cash flow generation. Our portfolio companies operate in volatile and uncertain environments...

Conference call will be held today, Tuesday, November 12 at 9:00 am ET CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2024. 3Q24 Financial HighlightsRevenues increased 40% to $667 thousand in the three months ended September 30, 2024 (the “3Q24”) compared to $477 thousand in the three months ended September 30, 2023 (the “3Q23”). Operating loss improved by 45% compared to the 3Q2023.Recent Operational HighlightsExpanded total covered lives to approximately 35 million compared to 4.5 million as of October 1, 2023. Recent medical policy coverages include:BCBS...

VANCOUVER, British Columbia, Nov. 12, 2024 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium company, today announced its financial and operating results for the fiscal first quarter 2025 ended September 30, 2024. “Our fiscal first quarter highlights demonstrate our commitment to doing what we say we’re going to do,” said David Park, Chief Executive Officer and Director of Standard Lithium. “We told you that we would pursue Government grants, and we have been conditionally approved for $225 million – one of the largest grant awards for a domestic critical minerals project – from the U.S. Department of Energy. The conditional grant is a testament to the world-class caliber of the South West Arkansas project and the good work...